Brain Abscesses Caused by Nocardia paucivorans in a Multiple Myeloma Patient Treated with Lenalidomide and Dexamethasone: a Case Report and Review of Literature
Jacopo Monticelli1, Roberto Luzzati1, Cristina Maurel1, Chiara Rosin1, Romina Valentinotti1 and Claudio Farina2
1 Unit of Infectious Diseases, University Hospital, Trieste, Italy.
2 Microbiology and Virology Institute, AO "Papa Giovanni XXIII", Bergamo, Italy.
Received: October 16, 2014
Accepted: December 18, 2014
Mediterr J Hematol Infect Dis 2015, 7(1): e2015011, DOI 10.4084/MJHID.2015.011
This article is available on PDF format at:
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We report the first case of multiple brain abscesses caused by Nocardia paucivorans in a patient suffering from multiple myeloma on treatment with lenalidomide and dexamethasone. N. paucivorans is a recently described species of the genus Nocardia, which is supposed to have a heightened neurotropism in cases of disseminated infection. Although nocardiosis itself is an uncommon infectious complication in multiple myeloma so far, nocardial brain abscess should be added to the spectrum of adverse effects due to this novel chemotherapy regimen.
A 70-year-old male was transferred to our unit from the intensive
care unit of a nearby hospital. He had had sudden onset
clonic seizures involving the right hemisoma and the assessment of
multiple brain abscesses by computerized tomography (CT) scan. The
patient was receiving empirical treatment with metronidazole and
cefotaxime. His past medical history included a 2-year-history of IgA
myeloma (International Staging System – II). The patient was initially
treated with melphalan plus prednisone plus bortezomib (4 cycles)
according to MPV protocol. Then, he started treatment with lenalidomide
and dexamethasone having completed eleven cycles of such regimen with
partial response. During the chemotherapy regimen the patient did not
receive a trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis and, at
time of admission, we discontinued the chemotherapy regimen for
myeloma. The patient suffered from a 2-month history of subcutaneous
abscess of unknown origin on the left shoulder. The lesion was drained,
and the microbiological analysis was not conclusive because of
mixed bacterial flora. The patient was living in a small rural hamlet.
He was a construction worker, but he retired 10 years before the
present hospital admission.
At hospital presentation, body temperature was 36.5 °C, heart rate was 92/min, blood pressure was 150/90 mmHg and Glasgow Coma Scale was 15/15. The patient was alert, oriented and no abnormal physical findings were shown, except for a painful hypoesthesia in the lateral and anterior sides of the left thigh, in the lateral side of the left leg and, on the dorsal side of the left foot. The subcutaneous abscess on the left shoulder completely resolved with no signs of local inflammation. Laboratory showed the following abnormalities: serum C-reactive protein 96.19 nmol/L (normal values inferior to 71.43 nmol/L), hemoglobin 90 g/L, white blood cells 3.9 x 109/L (51% neutrophil granulocytes). In addition, the analysis of peripheral blood lymphocytes subsets showed CD3+ 742 cells/µL, CD3+CD4+ 420 cells/µL (47%), CD3+CD8+ 241 cells/µL (27%), CD4+/CD8+ ratio 1.70, CD19+ 72 cells/µL. Serum protein electrophoresis showed a relative hypoalbuminemia (55.4%) according to the known monoclonal gammopathy (serum IgA 4490 mg/L, monoclonal component 3 g/L). The chest X-ray revealed a lower right lobe infiltrate associated with bilateral pleural effusion. A brain CT scan (Figure 1) with contrast medium showed 6 focal ring-enhancing lesions of which the largest one had a maximum diameter of 16 mm (left occipital lobe). All the lesions had a minimal perilesional oedema. The right frontal lesions led to a mass effect on the right lateral ventricle. At that time, the patient underwent CT-guided brain biopsy of a parietal lesion. A bioptic sample revealed branching Gram positive nocardioform rods. Then, cultures were incubated aerobically at 35°C for three weeks. All whitish, chalky and wet hay-smelling colonies (Figure 2) yielded on blood agar were stained by partial acid-fast method according to Kinyoun technique modified for nocardioforms (Figure 3).
|Figure 2. Whitish chalky colonies of N. paucivorans yielded on blood agar.|
|Figure 3. N. paucivorans hyphae. Staining by partial acid-fast method according to Kinyoun technique modified for nocardioforms. The vegetative hyphae are well developed with irregular branches.|
Minimal Inhibitory Concentrations' (MIC) testing was performed by the Epsilometer (E test, bioMérieux, France) testing. MICs' results were the following: amikacin 0.064 µg/mL, amoxicillin plus clavulanic acid (>256 µg/mL), ceftriaxone (0.75 µg/mL), cefepime (6 µg/mL), ciprofloxacin (0.047 µg/mL), clarithromycin (1 µg/mL), gentamicin (8 µg/mL), imipenem (0.19 µg/mL), linezolid (0.125 µg/mL), tobramycin (0.047 µg/mL), trimethoprim plus sulfonamide (0.002 µg/mL). Susceptibility testing was performed on Mueller Hinton Agar (bioMérieux). The results were read after 24 h of incubation at 37°C. Susceptibility testing was revised and interpreted according to CLSI criteria. In order to exclude concomitant pulmonary nocardiosis, a diagnostic bronchoscopy was done but the microbiological analysis of the bronchoalveolar lavage isolated only commensal microbial flora. As a matter of fact, based on the initial identification and the preliminary antimicrobial susceptibility testing, intravenous TMP-SMX plus meropenem were administered for 24 days. Such antibiotic regimen was switched to oral ciprofloxacin for an overall treatment period of 12 months. The patient is doing well, his painful hypoesthesias have disappeared; no more seizure episodes and adverse effects due to long term antibiotic therapy occurred. The brain CT-scan monitoring showed a progressive reduction of all cerebral lesions (Figure 1).
Human nocardiosis is usually recognized as a sporadic, community-acquired infection. Human nocardiosis affects both immunocompromised and immunocompetent hosts. Within the immunocompromising conditions, nocardiosis seems to affect primarily intravenous drug abusers, patients on systemic corticosteroids, AIDS patients, recipients of solid organ and bone marrow transplants, patients affected by chronic granulomatous diseases and hematologic malignancies. Host resistance to nocardial infection depends on cell-mediated immunity. Infection mainly occurs through direct skin inoculation or inhalation, and possible clinical manifestations are pulmonary nocardiosis, cutaneous and subcutaneous nocardiosis and systemic nocardiosis, including central nervous system (CNS) dissemination.[7-8] CNS nocardiosis can be the result of prior pulmonary infection or can exist on its own. A recent literature review on the nocardiosis reported that CNS involvement can manifest mainly as cerebral abscesses but also as meningitis or both brain abscess and meningitis. The major species reported among the patients in this literature review were Nocardia asteroides (35%), N. farcinica (19%), and N. cyriacigeorgica (6%), even if Nocardia nomenclature dramatically changed in the last years complicating all etiological consideration. Other less common species included Nocardia transvalensis (4%), N. brasilensis (3.6%), and N. otitidiscaviarum (2%) and others. Our patient had CNS nocardiosis due to N. paucivorans. The largest series of N. paucivorans infections published to date included 33 cases collected in northeast Australia over a 20-years span, with dissemination in at least 33% of cases and CNS infection in 80% of disseminated cases. Therefore, it was hypothesized that N. paucivorans had an enhanced neurotropism.[10-11]
Nocardial infection in multiple myeloma is quite a sporadic finding, often linked as a complication of bone marrow transplants. There is limited literature on nocardiosis in multiple myeloma patients that did not undergo bone marrow transplant, and there are still fewer cases of nocardial infections that occurred during novel anti-myeloma treatments. For instance, it was recently reported cases of brain abscesses by N. cyriacigeorgica in two patients treated with bortezomib. A PubMed search, crossing “Nocardia paucivorans” and “myeloma”, revealed no cases, and the N. paucivorans infections published so far in English literature did not occur in multiple myeloma patients.[10-11,13-15] Therefore, to the best of our knowledge, the present case is the first infection due to N. paucivorans in a patient affected by multiple myeloma.
Our patient had multiple risk factors for nocardiosis. The myeloma-related immunodeficiency includes mainly B cell dysfunction and cellular immunodeficiency[12,16] with significantly reduced numbers of NK and T cells and impaired T cells function. Lenalidomide is a synthetic derivative of thalidomide, used in multiple myeloma for its immunomodulatory properties. The molecule induces a IL-2-mediated primary T cell proliferation with a concomitant increase in IFN-γ production along with anti-angiogenic, anti-proliferative, and pro-apoptotic properties. However, lenalidomide combination therapy has shown to be prone to an increased risk of infections. In fact, a meta-analysis of efficacy and safety of lenalidomide for multiple myeloma showed an increased risk of infections comparing lenalidomide regimen versus placebo (RR = 1.98; 95% CI: 1.50 to 2.62). Therefore, an antibiotic prophylaxis should be considered as part of the treatment regimen. Bortezomib induces apoptosis preferentially in rapidly proliferating and neoplastic cells via inhibition of NF-κB activation. However, proteasome inhibition could influence the antigen processing and cytotoxic T-cell response and suppress essential immune functions of human CD4+ T cells. It has been shown that bortezomib therapy could increase the rate of opportunistic infectious complications, mainly within eight cycles of treatment during severe lymphocytopenia treatment-induced periods.[13,20] Corticosteroid therapy is widely associated with nocardial infections. Dexamethasone-based regimens in multiple myeloma increase the rate of bacterial infections (mainly encapsulated bacteria such as Staphylococcus aureus, and others including Enterobacteriaceae, Pseudomonas aeruginosa, mycobacteria), viral and micotic infections. An observational study of 13 patients collected over a 13-years period in two Spanish institutions showed that the most common risk factor for both pulmonary and disseminated nocardiosis was corticosteroid therapy (64% in the whole group of patients, 45.5% in disseminated nocardiosis patients). Dose and duration of steroid treatment in nocardiosis patients receiving corticosteroids prior to diagnosis varied widely in that study ranging from prednisone 40 mg/day for 15 days to prednisone 7.5 mg/day for 13 years.
Our patient received for the nocardiosis a combination regimen of TMP-SMX plus meropenem that was switched to a long term oral therapy with ciprofloxacin. Optimal antimicrobial treatment regimens have not been firmly established for nocardiosis, and the management of the disease must be individualized. Immunosuppressed patients and those with CNS disease should receive at least 12 months of antimicrobial therapy with the appropriate clinical monitoring. In CNS nocardiosis, the antibiotic regimen should include drugs with a favorable CNS penetration, as the ones we used for our patients.
In conclusion, this is the first report of multiple brain abscesses caused by N. paucivorans in a patient suffering from multiple myeloma. In this patient the risk factors for a nocardial infection included the hematological disease and chemotherapy. Among the various chemotherapy regimens, we suggest that corticosteroids and lenalidomide had a pivotal role as risk factors for nocardiosis in the present case. Although nocardial infection itself in multiple myeloma is an uncommon infectious complication so far, nocardial brain abscesses should be added to the spectrum of adverse effect due to the novel anti-myeloma drugs. We emphasize the importance in nocardial infections of obtaining the species identification and the strain susceptibility in order to guide the long term antibiotic therapy.
Finally, in our case etiological diagnosis was made possible by culture of brain biopsy. Other than the nocardial infection, the causes of focal brain infections in hematologic malignancies could include for instance neurotoxoplasmosis, zygomycosis, aspergillosis, fusariosis. Given the risks of misdiagnosis or delayed diagnosis, we highlight the importance of such invasive procedure, as a brain biopsy, to obtain samples for microbiological analysis in all cases of focal brain lesions, especially in the immunocompromised host.
Contributions, Conflict of Interest and Ethical Statement
We would like to thank doctor Gabriele Bazzocchi, Trieste (Italy), for providing the radiological imaging.
- Boiron P, Provost F. In-vitro susceptibility testing of Nocardia spp. and its taxonomic implication. J Antimicrobial Chemother 1988; 22: 623-629. http://dx.doi.org/10.1093/jac/22.5.623
- Mishra SK, Gordon R, Barnett DA Identification of nocardiae and actinomycetes of medical importance. J Clin Microbiol 1980; 11: 728-736 PMid:7000820 PMCid:PMC273495
and Laboratory Standards Institute (CLSI). Susceptibility Testing of
Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. CLSI document
M24-A2, March 2011, Wayne, Pennsylvania 19087-1898 USA, 2011.
- Yassin AF, Rainey FA, Burghardt J, Brzezinka H, Mauch M, Schaal KP. Nocardia paucivorans sp. nov. Int J Syst Evol Microbiol. 2000; 50 Pt 2: 803-9. http://dx.doi.org/10.1099/00207713-50-2-803 PMid:10758891
- Wauters G, Avesani V, Charlier J, Janssens M, Veneechoutte M, Delmée M. Distribution of Nocardia species in clinical samples and their routine rapid identification in the laboratory. J Clin Microbiol. 2005; 43: 2624-2628. http://dx.doi.org/10.1128/JCM.43.6.2624-2628.2005 PMid:15956375 PMCid:PMC1151960
- McNeil MM, Brown JM. The medically important aerobic actinomycetes: epidemiology and microbiology. Clin Microbiol Rev. 1994; 7: 357-417. PMid:7923055 PMCid:PMC358331
- Wilson JW. Nocardiosis: Updates and Clinical Overview. Mayo Clin Proc. 2012; 87: 403-407. doi: 10.1016/j.mayocp.2011.11.016. http://dx.doi.org/10.1016/j.mayocp.2011.11.016
- Corti ME, Villafa-e-Fioti MF. Nocardiosis: a review. Int J Infect Dis. 2003; 7: 243-50. http://dx.doi.org/10.1016/S1201-9712(03)90102-0
- Anagnostou T, Arvanitis M, Kourkoumpetis TK, Desalermos A, Carneiro HA, Mylonakis E. Nocardiosis of the central nervous system: experience from a general hospital and review of 84 cases from the literature. Medicine (Baltimore). 2014; 93:19-32. http://dx.doi.org/10.1097/MD.0000000000000012 PMid:24378740
- Gray TJ, Serisier DJ, Gilpin CM, Coulter C, Bowler SJ, McCormack JG. Nocardia paucivorans --a cause of disseminated nocardiosis. J Infect. 2007; 54: e95-8. http://dx.doi.org/10.1016/j.jinf.2006.05.005 PMid:16808975
- Hammoud M, Kraft C, Pulst-Korenberg J, Chenoweth C, Gregg KS. Disseminated Nocardia paucivorans infection in an immunocompetent host. Infection. 2014 15. [Epub ahead of print]
- Chouci-o C, Goodman SA, Greer JP, Stein RS, Wolff SN, Dummer JS. Nocardial infections in bone marrow transplant recipients. Clin Infect Dis. 1996; 23: 1012-9. http://dx.doi.org/10.1093/clinids/23.5.1012
- Pamukçuoglu M, Emmez H, Tunçcan OG, Oner AY, Cirak MY, Senol E, Sucak GT. Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections. Hematology. 2014; 19: 158-62. http://dx.doi.org/10.1179/1607845413Y.0000000108 PMid:23906027
- Eisenblätter M, Disko U, Stoltenburg-Didinger G, Scherübl H, Schaal KP, Roth A, Ignatius R, Zeitz M, Hahn H, Wagner J. Isolation of Nocardia paucivorans from the cerebrospinal fluid of a patient with relapse of cerebral nocardiosis. J Clin Microbiol. 2002; 40: 3532-4. http://dx.doi.org/10.1128/JCM.40.9.3532-3534.2002 PMid:12202613 PMCid:PMC130694
- Khan SH, Sanche SE, Robinson CA, Pirouzmand FN. paucivorans infection presenting as a brain abscess. Can J Neurol Sci. 2006; 33: 426-7. http://dx.doi.org/10.1017/S0317167100005436 PMid:17168173
- König C, Kleber M, Reinhardt H, Knop S, Wäsch R, Engelhardt M. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients. Ann Hematol. 2014; 93: 479-84. http://dx.doi.org/10.1007/s00277-013-1951-6 PMid:24318541
- Borrello I. Can we change the disease biology of multiple myeloma? Leuk Res. 2012; 36: S3-12.
- Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J. 2005 22;7: E14-9. http://dx.doi.org/10.1208/aapsj070103 PMid:16146335 PMCid:PMC2751493
- Yang B, Yu RL, Chi XH, Lu XC. Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2013 14;8: e64354.
- Jung SH, Bae SY, Ahn JS, Kang SJ, Yang DH, Kim YK, Kim HJ, Lee JJ. Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens. Int J Hematol. 2013 ;97: 382-7. http://dx.doi.org/10.1007/s12185-013-1270-7 PMid:23355264
- Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009 15;49:1211-25. http://dx.doi.org/10.1086/605664 PMid:19769539
- Martínez Tomás R, Menéndez Villanueva R, Reyes Calzada S, Santos Durantez M, Vallés Tarazona JM, Modesto Alapont M, Gobernado Serrano M. Pulmonary nocardiosis: risk factors and outcomes. Respirology. 2007;12: 394-400. http://dx.doi.org/10.1111/j.1440-1843.2007.01078.x PMid:17539844
R, Palacio C, Baluch A, Vargas J, Kenney P, Greene JN. Retrospective
analysis of opportunistic brain abscesses in patients with hematologic
malignancies. Infect Dis Clin Pract 2014;22: 96-103. http://dx.doi.org/10.1097/IPC.0b013e3182a1eca2